May 7th, 2015
Selections from Richard Lehman’s Literature Review: May 7th
Richard Lehman, BM, BCh, MRCGP
This week’s topics are a comparison of a retrievable inferior vena cava filter plus anticoagulation vs. anticogulation alone for recurrent PE, the cost effectiveness and population impact of statins for primary prevention in U.S. adults age 75 and older, and more.
January 9th, 2015
FDA Approves New Oral Anticoagulant from Daiichi Sankyo
Larry Husten, PHD
And then there were four. Late Thursday the FDA announced that it had approved edoxaban, the new oral anticoagulant manufactured by Daiichi Sankyo. The drug will be marketed under the brand name of Savaysa and joins three other new drugs in the large and important new oral anticoagulant marketplace: dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). All four drugs were […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?